Sign In
Buy PALI
$1.93
+0.0700 (+3.76%)
At Close: Jun 03, 2026
Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
08:30am, Friday, 16'th Jan 2026
PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis
Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108
08:15am, Wednesday, 07'th Jan 2026
PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibroste
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108
08:35am, Tuesday, 30'th Dec 2025
PALI-2108 is the first and only PDE4 inhibitor in development targeting the terminal ileum and colon for treatment of ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD) to address signif
Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025, albeit a holiday-shortened one once again. The major indices all finished the session modestly lower
Palisade Bio: Gut Prodrug For IBD With Catalysts
08:45pm, Monday, 22'nd Dec 2025
Palisade Bio's bull thesis centers on PALI-2108. This is a gut-targeted PDE4 prodrug aiming for local efficacy with fewer systemic PDE4 side effects. The main target indications are UC and FSCD, which
Palisade Bio (PALI) Upgraded to Buy: Here's What You Should Know
01:01pm, Friday, 19'th Dec 2025
Palisade Bio (PALI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
08:45am, Tuesday, 02'nd Dec 2025
Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference
08:45am, Tuesday, 25'th Nov 2025
Live webcast fireside chat on Thursday, December 4 th at 10:30 AM ET Carlsbad, CA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinica
Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher
10:56am, Monday, 10'th Nov 2025
After losing some value lately, a hammer chart pattern has been formed for Palisade Bio (PALI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate re
All You Need to Know About Palisade Bio (PALI) Rating Upgrade to Buy
01:01pm, Thursday, 06'th Nov 2025
Palisade Bio (PALI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
08:45am, Tuesday, 28'th Oct 2025
Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Palisade Bio, Inc. (NASDAQ: PALI)
11:50am, Monday, 20'th Oct 2025
NEW YORK , Oct. 20, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Palisade Bio, Inc. (NASDAQ: PALI) on behalf of the company's shareholders. The investigation seeks t
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
08:45am, Monday, 13'th Oct 2025
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn's disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical nee
